LncRNA Therapeutics for Precision Oncology
Non-small cell lung cancer (NSCLC) is the greatest cancer killer in Ireland and worldwide. Despite heroic efforts from physicians and researchers to improve patient care, 5-year survival remains <20%. Available therapies tend to be inactivated by drug resistance, and many also produce strong side effects.
The field of "RNA therapeutics" (RNATX) promises to create a new arsenal of drugs for common diseases including NSCLC. By targeting almost any cellular RNA, researchers can access a far greater target space than conventional therapies, and thereby select those with improved combinations of high effectiveness and low side-effects. RNATX depends on cheap, programmable antisense oligonucleotide (ASO) inhibitors, which may reduce the time and cost of developing new drugs.
In GOLD Lab, we seek to identify new targets for RNATX amongst the many thousands of long noncoding RNAs in the human genome. LncRNAs have some particular properties that makes them very promising drug targets, including tumour- and individual-specific expression and important roles in molecular networks promoting cancer hallmarks. However, lncRNAs also present special challenges due to their lack of protein-coding sequence, creating the need for new screening technologies to identify optimal therapeutic targets. GOLD Lab has developed both bioinformatic and experimental pipelines to meet these challenges, explained below.
Esposito R, Bosch N, Lanzós A, Polidori T, Pulido-Quetglas C, Johnson R.
Cancer Cell. 2019 Apr 15;35(4):545-557
Mutated lncRNAs that drive cancer
Tumours develop through the acquisition of driver mutations that enable cells to replicate uncontrollably and invade other sites. Genes containing driver mutations are attractive therapeutic targets, but it remains unknown whether these can include long noncoding RNAs. As part of our work in the International Cancer Genome Consortium's PCAWG (PanCancer Analysis of Whole Genomes) project, we have developed ExInAtor, a bioinformatic pipeline to identify driver lncRNAs using somatic mutations from whole tumour genomes.
ExInAtor, a pipeline for the discovery of cancer driver lncRNAs using somatic mutations. Lanzós A. et al, Sci Rep (2017).
LncRNA & Heart Regeneration
Heart regeneration is a biological process of utmost importance to medicine. It is known that lncRNAs play critical roles in the molecular networks mediating the response of cardiac cells to damage, such as caused by infarction. We use a variety of strategies to identify lncRNAs involved in this process.
Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Mei Xin et al. Nature Reviews Molecular Cell Biology volume 14, pages 529–541 (2013)
Project in collaboration with Thierry Pedrazzini (CHUV, Lausanne), Raffaela Santoro (Univ. of Zurich) and Mauro Giacca (King's College, London). Funded by Swiss National Science Foundation through the Sinergia programme.
Transposable elements: address codes for lncRNAs?
The sequence domains underlying long noncoding RNA (lncRNA) activities remain largely unknown. We have proposed that these domains can originate from neofunctionalised fragments of transposable elements (TEs), otherwise known as RIDLs (Repeat Insertion Domains of Long Noncoding RNA). A small but growing number of RIDLs have been identified.
We are interested in identifying RIDLs and understanding how they contribute to lncRNAs' biological activity. We have recently found evidence that a subset of TE types experience evolutionary selection in the context of lncRNA exons, and that their host lncRNAs tend to be functionally validated and associated with disease.
On the other hand, an emerging question in the lncRNA field, is how specific subcellular locations of lncRNAs are encoded in their primary sequence. We hypothesised that RIDLs may play a role in directing lncRNAs to subcellular compartments, and have found evidence to support this in a recent study. We use global localisation data from human cell lines to identify a role for evolutionarily-conserved L2b, MIRb and MIRc elements in regulating nuclear/cytoplasmic distribution of lncRNAs. These findings point to important roles for repetitive sequences in lncRNA localisation, and raise the question of what other activities they may encode.
For more information see these papers:
CRISPR-Cas9 tools for lncRNAs
CRISPR-Cas9 is a powerful and versatile genome-editing tool that has revolutionised the field of long noncoding RNA research. We have developed a suite of tools for single-gene and high-throughput functional analysis of lncRNAs. Our DECKO (Dual Excision CRISPR Knockout) vector system delivers paired sgRNAs for deletion of lncRNAs or other genomic elements. These can be designed using CRISPETa (CRISPR Paired Excision Tool), by both non-specialists and bioinformatics. Both DECKO and CRISPETa are scalable from single-gene to genome-wide experiments. Most recently, we have developed CASPR (CRISPR Analysis for Single and Paired RNA-guides), an end-to-end analysis tool for CRISPR screen analysis.
DECKO, a simple and scalable vector system for CRISPR-based deletion experiments. Aparicio-Prat E. et al. BMC Genomics (2015).
CRISPETa, a tool for the design of CRISPR deletion experiments. Pulido-Quetglas C. et al, PLOS Comp. (2017).
To date only 2% of lncRNAs has been functionally characterized, and little is known about their molecular mechanisms and transcript properties. Bioinformatic tools applied to the protein-coding world are generally ineffective for lncRNAs, complicating their classification and prediction of their functions. A major bottleneck is the lack of framework for categorizing lncRNAs and understanding how molecular functions are encoded in their sequence - or "sequence-function code".
In this context, we are especially focused on the characterisation of lncRNAs through the study of their subcellular localisation and embedded functional elements. See more information here.
Genomics depends on the availability of high quality annotations, or curated collections of genes. The worldwide reference annotation of lncRNAs in human and mouse is managed by GENCODE, a collaboration led by the Wellcome Trust Sanger Institute and funded by the National Human Genome Research Institute (NHGRI). Since 2010, RJ has contributed to this project, through the first landmark paper (Derrien, Johnson et al), and more recently through the development of Capture Long Read Sequencing (CLS) to improve and expand lncRNA annotations (Lagarde et al).
Find the raw CLS data here
Find the publication here